Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04586478Phase 2Recruiting
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in Non-Hodgkin lymphoma (NHL), sponsored by Juventas Cell Therapy Ltd.. Started Oct 2020; status: recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04586478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586478.